## CAH: Cardinal Health, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -1.4% below STRENGTH zone (4.0-10.0%); PEG 1.88 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($191.80)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 4
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Ember LifeSciences, Inc. announced that it has received $16.5 million in funding from Cardinal Health, Inc., Carrier Ventures, Sea Court Capital and other investors**
- Source: marketscreener.com | 20251216T165302 | Bullish | Relevance: 91%
- Ember LifeSciences, Inc. secured $16.5 million in funding on December 16, 2025, in a round led by new investor Sea Court Capital. Key participants included new investor Cardinal Health, Inc., and returning investor Carrier Ventures, alongside other individual investors. The company issued convertible preferred shares as part of this transaction.

**2. Safety Syringes Market Is Going to Boom |• BD (Becton Dickinson and Company) • Covidien (Medtronic)**
- Source: openPR.com | 20251216T090732 | Bullish | Relevance: 75%
- Worldwide Market Reports (WMR) predicts substantial growth for the "Safety Syringes Market" in the coming years, offering a comprehensive analysis of market dynamics, drivers, and regional insights. The report includes an enhanced 2032 Edition with updated data, competitive landscape analysis of key players like BD and Medtronic, and outlines segmental highlights by types and applications. It emphasizes robust research methodology and aims to provide actionable intelligence for business growth and investment decisions.

**3. Is Invesco Bloomberg Pricing Power ETF (POWA) a Strong ETF Right Now?**
- Source: Yahoo Finance | 20251216T110938 | Neutral | Relevance: 61%
- The Invesco Bloomberg Pricing Power ETF (POWA), launched in 2006, is a smart beta ETF designed for large-cap growth investors, focusing on companies with stable profit margins. Managed by Invesco, it tracks the BLOOMBERG PRICING POWER INDEX and has an expense ratio of 0.40%. The fund's top sector allocations include Healthcare, Information Technology, and Industrials, with its top 10 holdings accounting for nearly 24% of its assets.

**4. Cencora to acquire majority stake in OneOncology for $5B**
- Source: Fierce Healthcare | 20251216T170807 | Neutral | Relevance: 61%
- Cencora is set to acquire a majority stake in OneOncology for $5 billion, accelerating its buyout of the specialty practice network. This strategic move, which values OneOncology at $7.4 billion, will see Cencora controlling the majority interest while OneOncology’s affiliated practices retain a minority share. The deal is expected to close by the end of Q1 2026 and aligns with Cencora's pharmaceutical-centric growth strategy, enhancing its distribution avenues and operational support for oncology practices.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $243 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 11 ($0.00M) |
| Sells | 5 ($0.41M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Blackrock Inc.: 13.2% (+3.0%)
- Vanguard Group Inc: 13.0% (+0.8%)
- State Street Corpora: 5.2% (-3.0%)
- Geode Capital Manage: 2.7% (+1.5%)
- Wellington Managemen: 2.4% (+153.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.88 elevated, pricing in significant growth expectations. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $47.3B |
| Beta | 0.64 |
| 52W Range | $115.00 - $214.93 |
| Short Interest | 3.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.88 |
| Forward P/E | 18.0 |
| Current P/E | 20.2 |
| YoY Growth | 12.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -3.7% to -1.4% (+2.2% in 5 days), confirming momentum buildup. Below STRENGTH zone by 5.4pp (needs >4.0% for momentum thesis). MRS_5 turning positive (0.2%) - potential reversal signal. Long-term uptrend intact (above SMA200 at 1.25x) but short-term weakness (below SMA20). MACD histogram bearish (-1.69), momentum weakening. RSI neutral at 52. OFD pattern: +DBN (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.42% (CS: 27) | Neutral |
| RSI_14 | 52.1 | Neutral |
| MACD Histogram | -1.69 | Bearish |
| vs SMA20 | 0.979x | Below |
| vs SMA50 | 1.053x | Above |
| vs SMA200 | 1.251x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $199.04
- **Stop Loss:** $191.80 (3.6% risk)
- **Target:** $206.28 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 131
- **Position Value:** $26,074.24
- **Portfolio %:** 26.07%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with cautious positioning ahead of CPI data. VIX at moderate 16.87 with positive yield curve suggesting stable growth, but narrow breadth at 51.8% indicates selective participation. Banking sector optimism and corporate resilience provide support, though AI volatility creates pockets of uncertainty.*

### Earnings

**Next:** 2026-01-29 (Est: $2.30)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.17 | $2.55 | +17.3% |
| 2025Q2 | $2.03 | $2.08 | +2.4% |
| 2025Q1 | $2.15 | $2.35 | +9.4% |
| 2024Q4 | $1.76 | $1.93 | +9.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*